Document Type

Article

Publication Date

8-2023

Identifier

DOI: 10.1111/cts.13546; PMCID: PMC10432873

Abstract

Allergic conditions, such as asthma, chronic urticaria, atopic dermatitis (AD), and eosinophilic esophagitis, have long been treated with oral and topical steroids which resulted in negative off-target effects. However, newer biologic medications are increasingly being developed and approved for treatment of these conditions. These medications have a variety of mechanisms of action to target pathophysiology specific to these diseases. As biologics become more targeted, fewer off-target effects are seen improving tolerability for patients as well as expanded options for treatment of these conditions. This review discusses monoclonal antibody therapies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, and tralokinumab) including their safety and use in asthma, chronic urticaria, AD, and eosinophilic esophagitis.

Journal Title

Clin Transl Sci

Volume

16

Issue

8

First Page

1294

Last Page

1308

MeSH Keywords

Humans; Eosinophilic Esophagitis; Omalizumab; Asthma; Immunotherapy; Dermatitis, Atopic; Chronic Urticaria

Keywords

Humans; Eosinophilic Esophagitis; Omalizumab; Asthma; Immunotherapy; Dermatitis, Atopic; Chronic Urticaria

Comments

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Publisher's Link: https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13546

Download

Share

COinS